Women appeal to FDA on cancer drug Avastin
The cancer drug Avastin is slated to lose it's approval from the U.S. Food and Drug Administration for treating breast cancer.
Hearings are underway now. According to this Tribune blog post, some women and the drug's maker, Genentech, are hoping the agency reconsiders. Some claim it has worked for them, and losing the approval means insurance would likely no longer cover the cost.
The drug would remain approved for other kinds of cancer, and thus still available to doctors who wish to prescribe it "off label." But without insurance, that would likely put it out of reach.
The FDA approved Avastin for use in breast cancer in 2008 under a fast track system, pending further review. That review didn't show much effect on breast cancer, but some nasty side effects.
Anyone know of someone taking Avastin for breast cancer? It work for them? Should the FDA put this drug out of reach considering the study results?
Bloomberg photo








